Maze Therapeutics, Inc. (MAZE) Research

Maze Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the creation of precise small molecule medications for a range of ailments within the United States. Its primary therapeutic targets encompass renal, cardiovascular, and associated metabolic conditions, alongside obesity. The company's developmental pipeline highlights two leading drug candidates: MZE829, an oral small molecule engineered to inhibit apolipoprotein L1, which is currently in Phase II clinical studies for APOL1 kidney disease; and MZE782, another oral small molecule designed to block the solute transporter SLC6A19, presently in Phase I clinical evaluation for chronic kidney disease. The company, originally incorporated in 2017, adopted its current name, Maze Therapeutics, Inc., in September 2018, having previously been known as Modulus Therapeutics, Inc. It maintains its headquarters in South San Francisco, California.

Open Maze Therapeutics, Inc. (MAZE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.